Intellia names Jing L. Marantz chief medical officer

Bitget2026/10/13 11:34

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Intellia Therapeutics named Jing L. Marantz as executive vice president, chief medical officer, effective Oct. 26, 2026.
Marantz will lead translational, development, regulatory, medical affairs functions as Intellia prepares for a first in vivo gene-editing commercialization push.
She previously served as chief medical officer at Scholar Rock, overseeing development work that supported U.S. approval of ISEMBYLD.
Marantz also held senior roles at Krystal Biotech, Acceleron, Alnylam, Alexion, Biogen, ARIAD, Millennium Pharmaceuticals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130730PRIMZONEFULLFEED9843270) on October 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Intellia names Jing L. Marantz chief medical officer

You may also like

Crypto prices